is saxenda a glp 1 drug for Weight Loss: How It Works, Side Effects, and More Saxenda© – A New Treatment

J.et al (2016)

Retatrutide, Eli Lillys latest weight management and diabetes drug, appears to have outperformed the companys current product, tirzepatide (Mounjaro, Zepbound), in clinical trials

is supported by the American Heart AssociationBristol Myers Squibb Foundation through the Winn Diversity in Clinical Trials Clinical Investigator Leadership Award, and by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Physician-Scientist Career Development Award, Grant Number K12DK133995 (David Maahs, Linda DiMeglio, Multi-Center Program Directors)

Transition to Metabolic Constraint Collectively, GLP-1RA therapy is characterized by persistent reductions in nutrient inflow, increased reliance on lipid-derived substrates, suppression of anabolic pathways through AMPK signaling, and context-dependent modulation of adipose tissue lipolysis

10.1038/s41467-023-44067-4

Staying at a lower dose longer is a legitimate clinical strategy and often produces better tolerability with only modest reduction in weight loss speed